Jane Street Group LLC Sells 274,078 Shares of Replimune Group, Inc. (NASDAQ:REPL)

Jane Street Group LLC cut its stake in shares of Replimune Group, Inc. (NASDAQ:REPL - Free Report) by 51.1% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 262,248 shares of the company's stock after selling 274,078 shares during the quarter. Jane Street Group LLC owned approximately 0.38% of Replimune Group worth $2,874,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also bought and sold shares of the stock. State Street Corp grew its position in Replimune Group by 102.1% in the 3rd quarter. State Street Corp now owns 2,340,042 shares of the company's stock valued at $25,647,000 after purchasing an additional 1,182,181 shares during the period. Parkman Healthcare Partners LLC grew its holdings in shares of Replimune Group by 45.5% during the third quarter. Parkman Healthcare Partners LLC now owns 763,747 shares of the company's stock valued at $8,371,000 after buying an additional 238,747 shares during the last quarter. Arizona PSPRS Trust acquired a new position in shares of Replimune Group during the third quarter valued at about $834,000. Baker BROS. Advisors LP increased its position in shares of Replimune Group by 10.0% during the third quarter. Baker BROS. Advisors LP now owns 11,045,336 shares of the company's stock worth $121,057,000 after acquiring an additional 1,000,000 shares in the last quarter. Finally, Erste Asset Management GmbH acquired a new stake in shares of Replimune Group in the 3rd quarter worth about $133,000. 92.53% of the stock is owned by institutional investors.

Insider Activity

In other news, insider Konstantinos Xynos sold 7,246 shares of the company's stock in a transaction dated Monday, November 18th. The stock was sold at an average price of $10.78, for a total value of $78,111.88. Following the completion of the transaction, the insider now directly owns 109,885 shares in the company, valued at approximately $1,184,560.30. This represents a 6.19 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Sushil Patel sold 10,000 shares of the firm's stock in a transaction dated Monday, December 16th. The shares were sold at an average price of $12.42, for a total value of $124,200.00. Following the transaction, the chief executive officer now directly owns 202,014 shares in the company, valued at approximately $2,509,013.88. This represents a 4.72 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 8.80% of the company's stock.

Replimune Group Stock Performance

Shares of NASDAQ REPL traded up $0.48 during trading on Friday, reaching $12.49. 2,350,633 shares of the stock traded hands, compared to its average volume of 1,052,709. The company has a debt-to-equity ratio of 0.18, a current ratio of 10.11 and a quick ratio of 10.11. The stock has a market capitalization of $854.53 million, a P/E ratio of -4.10 and a beta of 1.26. Replimune Group, Inc. has a 52-week low of $4.92 and a 52-week high of $17.00. The company has a 50-day moving average of $12.25 and a 200-day moving average of $10.77.

Replimune Group (NASDAQ:REPL - Get Free Report) last issued its earnings results on Tuesday, November 12th. The company reported ($0.68) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.75) by $0.07. Analysts forecast that Replimune Group, Inc. will post -2.91 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities analysts have issued reports on REPL shares. JPMorgan Chase & Co. lifted their price target on Replimune Group from $14.00 to $17.00 and gave the company an "overweight" rating in a research note on Tuesday, September 24th. BMO Capital Markets upped their price target on Replimune Group from $14.00 to $18.00 and gave the stock an "outperform" rating in a report on Friday, November 22nd. HC Wainwright reissued a "buy" rating and issued a $17.00 price target on shares of Replimune Group in a research report on Friday, November 22nd. Roth Capital raised shares of Replimune Group to a "strong-buy" rating in a report on Tuesday, August 27th. Finally, Roth Mkm assumed coverage on shares of Replimune Group in a report on Tuesday, August 27th. They issued a "buy" rating and a $17.00 target price for the company. Seven research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, Replimune Group presently has a consensus rating of "Buy" and an average price target of $17.29.

Replimune Group Company Profile

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.